近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1.Jun Zhang*#, Xue-Feng Zhang#, Shou-Jie Huang, Ting Wu, Yue-Mei Hu,Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-HuiLiu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan,Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, Ning-Shao Xia*.Longer-Term Efficacy of a Vaccine against Hepatitis E. New Engl J Med 2015;372(10):914-22. (#：共第一作者，*：共通讯作者) （IF= 54.420） 2.Zhu FC#,Zhang J#, ZhangXF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, AiX, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW,Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthyadults: a large-scale, randomised, double-blind placebo-controlled, phase 3trial. Lancet, 2010, 376(9744): 895–902. (#：共第一作者)（IF=33.633） 3.Quan Yuan, Liu-WeiSong, Chun-Jen Liu, Zhuo Li, Ping-Guo Liu, Cheng-Hao Huang, Yan Yan,Sheng-Xiang Ge, Ying-Bin Wang, Cheng-Yuan Peng, Jun Zhang*, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen*,Ning-Shao Xia*. Hepatitis B core antibody level may help predict treatmentresponse in chronic hepatitis B patients. Gut, 2013,62(1):182-4.(共通讯作者)(IF=10.614) 4.Huang CH, Yuan Q,Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, GeSX, Zhang J*, Xia NS*.Influence of Mutations in Hepatitis B Virus Surface Protein on ViralAntigenicity and Phenotype in Occult HBV Strains from Blood Donors. JHepatol. 2012,57(4):720-9.（共通讯作者）(IF=9.334) 5.Zhang J#, Zhang XF#,Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, Yan Q, Yang CL, JiangHM, Huang HJ, Xian YL, J W-K Shih, M-H Ng, Li YM , Wang JZ*, Zhu FC* and XiaNS*: Protection against hepatitis E virus infection by naturally acquired and vaccine-inducedimmunity. Clin Microbiol Infect2014; 20: O397–O405. （#：共第一作者）(IF= 5.197) 6.Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z,Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-termantibody response of a hepatitis E vaccine. Vaccine. 2015, pii: S0264-410X(15)00839-7. doi:10.1016/j.vaccine.2015.06.050. (IF=3.492)（共通讯作者） 7.Wu T, Hu YM*, Li J, Chu K, Huang SJ, ZhaoH, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW,Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity andsafety of an E. coli-produced bivalent human papillomavirus (type 16 and 18)vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 2015, 33(32):3940-6.（共通讯作者）(IF=3.492) 8.Yue Zhang, Min Li, Fan Yang, Yufang Li,Zizheng Zheng, Xiao Zhang, Qingshan Lin, Ying Wang, Shaowei Li, Ningshao Xia, JunZhang*, and Qinjian Zhao*. Comparable quality attributes of hepatitis E vaccine antigen with andwithout adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother. 2015,11(5): 1129-39（共通讯作者）（IF= 2.131） 9.Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ,Yang CL, Cai JP, Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, ZhangJ*, Xia NS. Safety of an Escherichia coli-expressed bivalent humanpapillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-labelphase I clinical trial. Hum VaccinImmunother. 2014;10(2):1-7.（通讯作者）（IF= 2.131） 10.Yixin Chen, Chuan Li, Delei He, TongCheng, Shengxiang Ge, James Wai-Kuo Shih,Qinjian Zhao, Pei-Jer Chen, JunZhang∗, NingshaoXia∗, Antigenic analysis of divergentgenotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonalantibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine 2013, 31:425-430 (共通讯作者) (IF=3.492) 11.Zhang J, Shih JW*, Wu T, Li SW, Xia NS: Development of the hepatitis E vaccine:from bench to field. Sem Liver Dis2013, 33(1):79-88. (IF=8.274) 12.Zhang J, Li SW, Wu T, Zhao Q, Ng MH, Xia NS. HepatitisE virus: neutralizing sites, diagnosis,and protective immunity. Rev Med Virol.2012,22(5):339-49.(IF=7.615) 13.Huang SJ, ZhangXF, Jiang HM, Yan Q, Ai X, Wang YJ, Cai JP, Jiang L, Wu T, Wang ZZ, Guan L,Shih JWK, Ng MH, Zhu FC, Zhang J*,Xia NS. Profile of Acute Infectious Markers in Sporadic Hepatitis E. PLoSOne. 2010, 5(10): e13560.（通讯作者）(IF=4.411) 14.Yu H, Yuan Q, GeSX, Wang HY, Zhang YL, Chen QR, ZhangJ*, Chen PJ, Xia NS. Molecular and phylogenetic Analyses Suggest anAdditional Hepatitis B Virus Genotype “I”, PLoS One. 2010, 5(2):e9297.（通讯作者）(IF=4.411) 15.Yuan Q, Ou SH,Chen CR*, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AET, ShihJWK, Zhang J*, Xia NS.Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors inSoutheast China, J Clin Microbiol, 2010, 48: 357–362. （共通讯作者）（IF=4.220） 16.Zhu FC, Huang SJ,Wu T, Zhang XF, Wang ZZ, Ai X, Yan Q, Yang CL, Cai JP, Jiang HM, Wang YJ,Mun-Hon Ng, Zhang J *, XiaNS. Epidemiology of Zoonotic Hepatitis E: A Community-Based Surveillance Studyin a Rural Population in China. PLoS One, 2014, 9(1): e87154 （通讯作者）（IF=3.534） 17.Li A, Yuan Q,Huang ZY, Fan J, Guo RY, Lou B, Zheng Q, Ge SX*, Chen YX, Su ZJ, Yeo AET, ChenY, Zhang J*, Xia NS. NovelDouble-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody. ClinVac Immunol 2010,17:464–469.（共通讯作者）（IF =2.471） 18.Yuan Q, Ge SX,Xiong JH, Yan Q, Li Z, Hao XK, Tian DY, Niu JJ, Su ZJ, Chen CR, Shih JWK, Zhang J∗,Xia NS. A novel immunoassay for PreS1 and/or core-related antigens fordetection of HBsAg variants. J Virol Methods.2010;168(1-2):108-113.（通讯作者）（IF =2.139） 19.Zhang J, Liu CB, Li RC, LiYM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX, Xiong JH, Shih JW, Ng MH,Xia NS. (2009) Randomized-controlled phase II clinical trial of a bacteriallyexpressed recombinant hepatitis E vaccine. Vaccine, 27:1869-1874 (IF =3.377) 20.Wu T., Wu X.L., OuS.H., Lin C.X., Cheng T., Li S.W., Ng M.H., Zhang J.,*XiaN.S.*, Difference of T cell and B cell activation in two homologousproteins with similar antigenicity but great distinct immunogenicity. MolImmunol, 2007, 44(12): 3261-3266(IF =3.742)（共通讯作者）
京公网安备 11010802027423号